









市場行情
/
股票
/
nasdaq-mrus
/

Merus NV

MRUS

96.910USD

+0.010+0.01%

收盤 12/24, 13:00（美東）報價延遲15分鐘

7.35B總市值

虧損本益比TTM



Merus NV

96.910

+0.010+0.01%

概覽公司財務分析

概覽

公司

財務

分析

關於 Merus NV 公司

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Merus NV簡介



公司代碼MRUS

公司名稱Merus NV

上市日期May 19, 2016

CEOLundberg (Sven Ante)

員工數量260

證券類型Ordinary Share

年結日May 19

公司地址Yalelaan 62

城市UTRECHT

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Netherlands

郵編3584 CM

電話310302538800

網址https://merus.nl/

公司代碼MRUS

上市日期May 19, 2016

CEOLundberg (Sven Ante)

Merus NV公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Sven Ante (Bill) Lundberg, M.D.

President, Chief Executive Officer, Executive Director

168.44K

-15.24%

Dr. Anand Mehra, M.D.

Non-Executive Independent Chairman of the Board

Mr. Peter B. Silverman, J.D.

Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal

Ms. Sherri Spear

Investor Relations and Corporate Communications

Mr. Jason Haddock

Director

Dr. Maxine Gowen, Ph.D.

Non-Executive Independent Director

Mr. Leonard (Len) Kanavy

Non-Executive Independent Director

Dr. Victor Sandor, M.D.

Non-Executive Independent Director

Mr. Gregory D. (Greg) Perry

Chief Financial Officer

Mr. Paolo Pucci

Non-Executive Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Sven Ante (Bill) Lundberg, M.D.

President, Chief Executive Officer, Executive Director

168.44K

-15.24%

Dr. Anand Mehra, M.D.

Non-Executive Independent Chairman of the Board

Mr. Peter B. Silverman, J.D.

Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal

Ms. Sherri Spear

Investor Relations and Corporate Communications

Mr. Jason Haddock

Director

Dr. Maxine Gowen, Ph.D.

Non-Executive Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月21日週日

持股股東

股東類型

持股股東

佔比

Genmab A/S

94.86%

Paradigm BioCapital Advisors LP

5.77%

Avoro Capital Advisors LLC

4.67%

Commodore Capital LP

4.65%

Deerfield Management Company, L.P.

4.02%

持股股東

佔比

Genmab A/S

94.86%

Paradigm BioCapital Advisors LP

5.77%

Avoro Capital Advisors LLC

4.67%

Commodore Capital LP

4.65%

Deerfield Management Company, L.P.

4.02%

股東類型

持股股東

佔比

Corporation

96.78%

Hedge Fund

40.76%

Investment Advisor/Hedge Fund

29.65%

Investment Advisor

15.32%

Research Firm

2.54%

Private Equity

1.78%

Venture Capital

1.47%

Bank and Trust

0.65%

Pension Fund

0.64%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

434

77.32M

101.98%

-5.60M

2025Q2

411

75.46M

99.77%

-10.50M

2025Q1

420

74.82M

101.12%

-10.15M

2024Q4

398

74.69M

108.18%

-7.45M

2024Q3

373

72.99M

107.03%

-6.71M

2024Q2

355

69.91M

103.77%

+7.77M

2024Q1

315

57.35M

97.63%

-5.32M

2023Q4

282

57.36M

99.41%

-5.55M

2023Q3

268

57.60M

100.50%

+2.76M

2023Q2

260

49.90M

100.83%

+114.35K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Paradigm BioCapital Advisors LP

4.28M

5.65%

+727.89K

+20.48%

Jun 30, 2025

Avoro Capital Advisors LLC

3.16M

4.16%

+155.56K

+5.19%

Jun 30, 2025

Commodore Capital LP

3.52M

4.65%

-947.84K

-21.19%

Jun 30, 2025

Deerfield Management Company, L.P.

3.38M

4.47%

+210.70K

+6.64%

Jun 30, 2025

Westfield Capital Management Company, L.P.

2.04M

2.69%

+541.17K

+36.05%

Jun 30, 2025

RTW Investments L.P.

4.00M

5.28%

-168.84K

-4.05%

Jun 30, 2025

Fidelity Management & Research Company LLC

6.22M

8.2%

+593.98K

+10.56%

Jun 30, 2025

Woodline Partners LP

1.54M

2.04%

+142.73K

+10.19%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

AltShares Merger Arbitrage ETF

3.3%

NYLI Merger Arbitrage ETF

3.1%

ALPS Medical Breakthroughs ETF

2.89%

Goldman Sachs Hedge Industry VIP ETF

2.75%

ProShares Merger ETF

2.74%

First Trust IPOX Europe Equity Opportunities ETF

2.61%

Tema Oncology ETF

2.61%

Invesco Dorsey Wright Healthcare Momentum ETF

1.4%

Harbor Health Care ETF

1.29%

AltShares Event-Driven ETF

1.23%

AltShares Merger Arbitrage ETF

佔比3.3%

NYLI Merger Arbitrage ETF

佔比3.1%

ALPS Medical Breakthroughs ETF

佔比2.89%

Goldman Sachs Hedge Industry VIP ETF

佔比2.75%

ProShares Merger ETF

佔比2.74%

First Trust IPOX Europe Equity Opportunities ETF

佔比2.61%

Tema Oncology ETF

佔比2.61%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比1.4%

Harbor Health Care ETF

佔比1.29%

AltShares Event-Driven ETF

佔比1.23%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Merus NV的前五大股東是誰？



Merus NV的前五大股東如下：
Paradigm BioCapital Advisors LP
持有股份：4.28M
佔總股份比例：5.65%。
Avoro Capital Advisors LLC
持有股份：3.16M
佔總股份比例：4.16%。
Commodore Capital LP
持有股份：3.52M
佔總股份比例：4.65%。
Deerfield Management Company, L.P.
持有股份：3.38M
佔總股份比例：4.47%。
Westfield Capital Management Company, L.P.
持有股份：2.04M
佔總股份比例：2.69%。